Adaptación de la terapia anti-Her2 durante la adyuvancia en cáncer de mama localizado: a propósito de un caso clínico

Adaptación de la terapia anti-Her2 durante la adyuvancia en cáncer de mama localizado: a propósito de un caso clínico

El cáncer de mama HER2 positivo localizado representa un subtipo agresivo con un alto riesgo de recurrencia. A pesar de los avances en la terapia adyuvante, una proporción significativa de pacientes no logra una respuesta patológica completa después del tratamiento neoadyuvante, lo que aumenta el ri...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea D. Sumba-Chávez, Daniel Mata-Cano, Monserrat Llobera-Serentill
Format:	Article
Language:	Spanish
Published:	Universidad Nacional Hermilio Valdizán 2025-04-01
Series:	Revista Peruana de Investigación en Salud
Subjects:	cáncer de mama HER2 positivo quimioterapia neoadyuvante terapia adyuvante terapi antiHer2 neumonitis
Online Access:	https://revistas.unheval.edu.pe/index.php/repis/article/view/2276
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cáncer de mama HER2-bajo: una nueva era en terapias dirigidas
by: Benjamín Walbaum, MD, et al.
Published: (2025-05-01)

Recomendaciones actuales basadas en evidencia sobre el manejo de cáncer de vesícula biliar en estadios avanzados en los últimos 5 años
by: Elizabeth Cramer Jenkins, et al.
Published: (2025-03-01)

Survival outcomes for HER2-low breast cancer: Danish national data
by: Michael Sode, et al.
Published: (2024-11-01)

Analysis of factors influencing the efficacy of NAC and prognosis between HER2-zero and HER2-low HR negative breast cancer
by: Jing-Jing Liu, et al.
Published: (2024-11-01)

PE-074 Perfil de tratamento e custos da jornada do câncer de mama em uma operadora de saúde: uma análise de mundo real
by: Harli Pasquini-Netto, et al.
Published: (2025-03-01)

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
by: Lucía Gandullo‐Sánchez, et al.
Published: (2020-04-01)

Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer
by: Yisun Jeong, et al.
Published: (2024-12-01)

Fully automatic HER2 tissue segmentation for interpretable HER2 scoring
by: Mathias Öttl, et al.
Published: (2025-04-01)

Accuracy of human epidermal growth factor receptor 2 (HER2) immunohistochemistry scoring by pathologists in breast cancer, including the HER2-low cutoff
by: Agata Wróbel, et al.
Published: (2025-04-01)

Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China
by: Hong Lv, et al.
Published: (2025-03-01)

Counseling of women through oncological treatment and mastectomy as a repercussion from breast cancer / Enfrentamiento de mujeres ante del tratamiento oncológico y de la mastectomía como repercusión del cáncer de mama
by: Francieli Carolina Novaski da Silva, et al.
Published: (2021-05-01)

Counseling of women through oncological treatment and mastectomy as a repercussion from breast cancer / Enfrentamiento de mujeres ante del tratamiento oncológico y de la mastectomía como repercusión del cáncer de mama
by: Francieli Carolina Novaski da Silva, et al.
Published: (2021-05-01)

Counseling of women through oncological treatment and mastectomy as a repercussion from breast cancer / Enfrentamiento de mujeres ante del tratamiento oncológico y de la mastectomía como repercusión del cáncer de mama
by: Francieli Carolina Novaski da Silva, et al.
Published: (2021-05-01)

Counseling of women through oncological treatment and mastectomy as a repercussion from breast cancer / Enfrentamiento de mujeres ante del tratamiento oncológico y de la mastectomía como repercusión del cáncer de mama
by: Francieli Carolina Novaski da Silva, et al.
Published: (2020-07-01)

HER2-Positive Serous Endometrial Cancer Treatment: Current Clinical Practice and Future Directions
by: Dimitrios Papageorgiou, et al.
Published: (2024-12-01)

Potential prognostic value of HER2/CEP17 FISH ratio in HER2-positive non-metastatic breast cancer: a real-world study
by: Fangchao Zheng, et al.
Published: (2025-05-01)

Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review
by: Javier Muñoz, et al.
Published: (2025-06-01)

Ecografía pulmonar y neumonitis por aspiración de queroseno
by: Luis Fong Pantoja, et al.
Published: (2023-01-01)

Carcinoma Metaplásico de Mama: Diagnóstico e Abordagem Multidisciplinar em Caso de Subtipo Raro
by: Rodrigo Sousa Brandão, et al.
Published: (2025-03-01)

Chemotherapy-related fatigue: the perspective of women with breast câncer / Fadiga secundária à quimioterapia na perspectiva da mulher com câncer de mama
by: Cristiane Soares Campos, et al.
Published: (2021-05-01)

Chemotherapy-related fatigue: the perspective of women with breast câncer / Fadiga secundária à quimioterapia na perspectiva da mulher com câncer de mama
by: Cristiane Soares Campos, et al.
Published: (2021-05-01)

Chemotherapy-related fatigue: the perspective of women with breast câncer / Fadiga secundária à quimioterapia na perspectiva da mulher com câncer de mama
by: Cristiane Soares Campos, et al.
Published: (2020-07-01)

Chemotherapy-related fatigue: the perspective of women with breast câncer / Fadiga secundária à quimioterapia na perspectiva da mulher com câncer de mama
by: Cristiane Soares Campos, et al.
Published: (2021-05-01)

Nursing diagnostics associated with the quality of life of women with breast cancer in chemotherapy / Diagnósticos de enfermagem associados a qualidade de vida de mulheres com câncer de mama em quimioterapia
by: Shirley Dósea dos Santos Naziazeno, et al.
Published: (2021-05-01)

Nursing diagnostics associated with the quality of life of women with breast cancer in chemotherapy / Diagnósticos de enfermagem associados a qualidade de vida de mulheres com câncer de mama em quimioterapia
by: Shirley Dósea dos Santos Naziazeno, et al.
Published: (2021-05-01)

Nursing diagnostics associated with the quality of life of women with breast cancer in chemotherapy / Diagnósticos de enfermagem associados a qualidade de vida de mulheres com câncer de mama em quimioterapia
by: Shirley Dósea dos Santos Naziazeno, et al.
Published: (2021-05-01)

Nursing diagnostics associated with the quality of life of women with breast cancer in chemotherapy / Diagnósticos de enfermagem associados a qualidade de vida de mulheres com câncer de mama em quimioterapia
by: Shirley Dósea dos Santos Naziazeno, et al.
Published: (2020-07-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Advances in research and current challenges in the treatment of advanced HER2-low breast cancer
by: Qiang Qin
Published: (2025-03-01)

HER2-low breast cancer. Diagnostics, treatment and its adverse events
by: Hanna Bartkowiak, et al.
Published: (2024-12-01)

Prevalencia de la neutropenia en una institución de IV nivel en la ciudad de Barranquilla
by: Ángel Hernández Lastra, et al.
Published: (2025-01-01)

STUDI IN SILICO KOMPLEKS LIGAND-RESEPTOR EUGENOL DAUN BASIL (Ocimum basilicum L.) DENGAN RESEPTOR HER2 PADA NON-SMALL CELL LUNG CANCER (NSCLC) DENGAN KONTROL GEFITINIB
by: Martina Kurnia Rohmah
Published: (2017-09-01)

HER2-Low Breast Cancer—Current Knowledge and Future Directions
by: Abeer M. Shaaban, et al.
Published: (2025-04-01)

Clinical characteristics and therapeutic direction of HER2 low-expression breast cancer
by: Linlin Zhou, et al.
Published: (2025-02-01)

Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation
by: Liang ZHANG, et al.
Published: (2025-02-01)

Purine–Hydrazone Scaffolds as Potential Dual EGFR/HER2 Inhibitors
by: Fatemah S. Albalawi, et al.
Published: (2025-07-01)

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report
by: Oliver Illini, et al.
Published: (2024-01-01)

Current approaches to the treatment of HER2‑positive breast cancer with brain metastases
by: T. Yu. Semiglazova, et al.
Published: (2021-06-01)

Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy
by: Charles E. Geyer, Jr., et al.
Published: (2025-06-01)

Prediction model for assessing HER2 status patient with invasive ductal carcinoma based on clinical parameters and ultrasound features: a dual-center study
by: Lei Zhou, et al.
Published: (2025-07-01)